Get the Stockscreener App
2.36
10.80%
0.23
After Hours:
2.40
0.04
+1.69%
Immunitybio Inc stock is traded at $2.36, with a volume of 21.33M.
It is up +10.80% in the last 24 hours and down -8.53% over the past month.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
See More
Previous Close:
$2.13
Open:
$2.295
24h Volume:
21.33M
Relative Volume:
2.21
Market Cap:
$2.32B
Revenue:
$1.31M
Net Income/Loss:
$-597.65M
P/E Ratio:
-2.433
EPS:
-0.97
Net Cash Flow:
$-425.62M
1W Performance:
+13.46%
1M Performance:
-8.53%
6M Performance:
-4.07%
1Y Performance:
-53.73%
1-Day Range:
$2.25
$2.45
1-Week Range:
$2.05
$2.45
52-Week Range:
$1.83
$5.1599
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
2.36 | 2.10B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
Immunitybio Inc Stock (IBRX) Latest News
Why ImmunityBio (IBRX) Is Up 13.5% After Strong Q3 Anktiva Revenue Surge Announced at Jefferies London - simplywall.st
ImmunityBio Stock Surges Amid Growing Demand and Clinical Success - StocksToTrade
ImmunityBio’s Remarkable Growth: Unpacking the Surge - StocksToTrade
ImmunityBio Explores Innovations in Cancer Treatment - timothysykes.com
ImmunityBio (IBRX): Evaluating Valuation After Q3 Revenue Growth and Operational Improvements - simplywall.st
A Fresh $16 Million Bet on ImmunityBio: What Investors Should Know - AOL.com
What to know about Anktiva, the cancer drug that doesn’t use chemotherapy - NewsNation
How does nonchemotherapy cancer treatment Anktiva work? - NewsNation
Q3 2025 Contract Research Organization (CRO) Activity and Intel Report Featuring ICON, Astrazeneca, Akesobio, CSPPC Pharmaceutical, ImmunityBio, and Boryung - Yahoo Finance
H.C. Wainwright Asserts Buy Rating on Immunitybio Inc. (IBRX) as Net Loss Narrows on Robust Product Revenue - MSN
Can ImmunityBio Inc. (26CA) stock sustain free cash flow2025 Trading Volume Trends & Weekly High Potential Alerts - newser.com
Why analysts upgrade ImmunityBio Inc. stockMarket Risk Report & Consistent Income Trade Recommendations - newser.com
Intraday pattern recognizer results for ImmunityBio Inc.July 2025 Short Interest & Safe Capital Growth Trade Ideas - newser.com
How ImmunityBio Inc. (26CA) stock responds to bond marketWeekly Profit Summary & AI Driven Stock Price Forecasts - newser.com
Can ImmunityBio Inc. (26CA) stock test all time highsJuly 2025 Summary & Daily Technical Stock Forecast Reports - newser.com
Will ImmunityBio Inc. (26CA) stock extend growth storyRate Hike & Verified Chart Pattern Signals - newser.com
Biotech Billionaire Soon-Shiong Sued Over ImmunityBio Stock Move - MSN
Heights Capital Walks From Archer Aviation: What It Means for Investors - The Motley Fool
Why ImmunityBio Inc. (26CA) stock is a strong analyst pickInsider Selling & Stock Portfolio Risk Management - newser.com
What dividend safety rating applies to ImmunityBio Inc. (26CA) stockMarket Trend Review & Weekly Hot Stock Watchlists - newser.com
Is ImmunityBio Inc. (26CA) stock a buy before earnings resultsPortfolio Update Report & Free Daily Entry Point Trade Alerts - newser.com
ImmunityBio: Checking The Boxes Of A True Commercial-Stage Biotech (NASDAQ:IBRX) - Seeking Alpha
Is ImmunityBio Inc. (26CA) stock a safe buy pre earnings2025 Support & Resistance & Daily Oversold Bounce Ideas - newser.com
Applying big data sentiment scoring on ImmunityBio Inc.Trade Signal Summary & Safe Capital Allocation Plans - newser.com
Why ImmunityBio Inc. (26CA) stock is upgraded to buyAnalyst Upgrade & Momentum Based Trading Signals - newser.com
Editor: 【Stock Selection Techniques】 - newser.com
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
1.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):